PDF herunterladen
Kardiologie up2date 2009; 5(3): 206-212
DOI: 10.1055/s-0029-1215272
Hotline – Koronare Herzerkrankung und Atherosklerose

© Georg Thieme Verlag KG Stuttgart · New York

Die JUPITER-Studie: Antworten und Fragen?

Felix  Post, Thomas  Münzel
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Oktober 2009 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik

Abstract

Over the last years the indication for a therapy with statins has been expanded. The recently published JUPITER-Trial (Jusfication for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) was conducted to test, if indication for statin therapy can be expanded even further. The study compared rosuvastatin 20 mg daily vs placebo in apparently healthy people with levels of low-density lipoprotein cholesterol (LDL) lower than 130 mg/dL but showed an elevation (≥ 2 mg/L) of high-sensitivity C-reactive protein (hs-CRP). Rosuvastatin treatment lowered LDL-C levels by 50 % and hs-CRP levels by 37 %, accompanied by a 44% relative risk reduction in the composite end point of unstable angina, revascularization, and confirmed death from cardiovascular causes. The number-needed-to treat was 95 patients over a 2 year period to prevent one event. We would like to discuss this study with current data on statin therapy and focus on possible implications of the study results.

Literatur

  • 1 Ridker P M, Danielson E, Fonseca F A. et al . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.  N Engl J Med. 2008;  359 2195-2207
    CrossrefPubMedGoogle Scholar
  • 2 Robinson J G, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.  J Am Coll Cardiol. 2005;  46 1855-1862
    CrossrefPubMedGoogle Scholar
  • 3 Topol E J. Intensive statin therapy – a sea change in cardiovascular prevention.  N Engl J Med. 2004;  350 1562-1564
    CrossrefPubMedGoogle Scholar
  • 4 Cohen D J, Carrozza J P, Baim D S. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.  N Engl J Med. 1999;  341 1853-1854; author reply 1854 – 1855
    CrossrefPubMedGoogle Scholar
  • 5 Nissen S E, Nicholls S J, Sipahi I. et al . Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.  JAMA. 2006;  295 1556-1565
    CrossrefPubMedGoogle Scholar
  • 6 Liao J K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.  Am J Cardiol. 2005;  96 24F-33F
    PubMedGoogle Scholar
  • 7 Shishehbor M H, Brennan M L, Aviles R J. et al . Statins promote potent systemic antioxidant effects through specific inflammatory pathways.  Circulation. 2003;  108 426-431
    CrossrefPubMedGoogle Scholar
  • 8 Shishehbor M H, Patel T, Bhatt D L. Using statins to treat inflammation in acute coronary syndromes: Are we there yet?.  Cleve Clin J Med. 2006;  73 760-766
    CrossrefPubMedGoogle Scholar
  • 9 Takemoto M, Liao J K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.  Arterioscler Thromb Vasc Biol. 2001;  21 1712-1719
    CrossrefPubMedGoogle Scholar
  • 10 Ridker P M, Cannon C P, Morrow D. et al . C-reactive protein levels and outcomes after statin therapy.  N Engl J Med. 2005;  352 20-28
    CrossrefPubMedGoogle Scholar
  • 11 Ridker P M, Rifai N, Clearfield M. et al . Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.  N Engl J Med. 2001;  344 1959-1965
    CrossrefPubMedGoogle Scholar
  • 12 Shishehbor M H, Bhatt D L, Topol E J. Using C-reactive protein to assess cardiovascular disease risk.  Cleve Clin J Med. 2003;  70 634-640
    CrossrefPubMedGoogle Scholar
  • 13 Ridker P M. Novel risk factors and markers for coronary disease.  Adv Intern Med. 2000;  45 391-418
    PubMedGoogle Scholar
  • 14 Ridker P M, Buring J E, Shih J. et al . Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.  Circulation. 1998;  98 731-733
    CrossrefPubMedGoogle Scholar
  • 15 Rifai N, Ridker P M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.  Clin Chem. 2001;  47 403-411
    PubMedGoogle Scholar
  • 16 Zacho J, Tybjaerg-Hansen A, Jensen J S. et al . Genetically elevated C-reactive protein and ischemic vascular disease.  N Engl J Med. 2008;  359 1897-1908
    CrossrefPubMedGoogle Scholar
  • 17 Nissen S E, Tuzcu E M, Schoenhagen P. et al . Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.  N Engl J Med. 2005;  352 29-38
    CrossrefPubMedGoogle Scholar
  • 18 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
    CrossrefPubMedGoogle Scholar
  • 19 Graham I, Atar D, Borch-Johnsen K. et al . European guidelines on cardiovascular disease prevention in clinical practice: executive summary.  Eur Heart J. 2007;  28 2375-2414
    CrossrefPubMedGoogle Scholar
  • 20 Grundy S M, Cleeman J I, Merz C N. et al . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.  Circulation. 2004;  110 227-239
    CrossrefPubMedGoogle Scholar
  • 21 Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results.  Int J Clin Pract. 2002;  56 53-56
    PubMedGoogle Scholar
  • 22 Cannon C P, Braunwald E, McCabe C H. et al . Intensive versus moderate lipid lowering with statins after acute coronary syndromes.  N Engl J Med. 2004;  350 1495-1504
    CrossrefPubMedGoogle Scholar
  • 23 LaRosa J C, Grundy S M, Waters D D. et al . Intensive lipid lowering with atorvastatin in patients with stable coronary disease.  N Engl J Med. 2005;  352 1425-1435
    CrossrefPubMedGoogle Scholar
  • 24 Liem A H, van Boven A J, Veeger N J. et al . Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial.  Eur Heart J. 2002;  23 1931-1937
    CrossrefPubMedGoogle Scholar
  • 25 Patel T N, Shishehbor M H, Bhatt D L. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis.  Eur Heart J. 2007;  28 664-672
    CrossrefPubMedGoogle Scholar
  • 26 Pedersen T R, Faergeman O, Kastelein J J. et al . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.  JAMA. 2005;  294 2437-2445
    CrossrefPubMedGoogle Scholar
  • 27 Pitt B, Waters D, Brown W V. et al . Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.  N Engl J Med. 1999;  341 70-76
    CrossrefPubMedGoogle Scholar
  • 28 Serruys P W, de Feyter P, Macaya C. et al . Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.  JAMA. 2002;  287 3215-3222
    CrossrefPubMedGoogle Scholar
  • 29 Cushman M, Arnold A M, Psaty B M. et al . C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study.  Circulation. 2005;  112 25-31
    CrossrefPubMedGoogle Scholar
  • 30 Ridker P M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.  Circulation. 2001;  103 1813-1818
    CrossrefPubMedGoogle Scholar
  • 31 Ridker P M, Hennekens C H, Buring J E, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.  N Engl J Med. 2000;  342 836-843
    CrossrefPubMedGoogle Scholar
  • 32 Albert M A, Danielson E, Rifai N, Ridker P M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.  JAMA. 2001;  286 64-70
    CrossrefPubMedGoogle Scholar
  • 33 Ridker P M, Rifai N, Pfeffer M A. et al . Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.  Circulation. 1999;  100 230-235
    PubMedGoogle Scholar
  • 34 Pfister R, Hellmich M. Multiple biomarkers and cardiovascular risk.  N Engl J Med. 2008;  359 760; author reply 761
    PubMedGoogle Scholar
  • 35 Schunkert H, Samani N J. Elevated C-reactive protein in atherosclerosis – chicken or egg?.  N Engl J Med. 2008;  359 1953-1955
    CrossrefPubMedGoogle Scholar
  • 36 Danesh J, Wheeler J G, Hirschfield G M. et al . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.  N Engl J Med. 2004;  350 1387-1397
    CrossrefPubMedGoogle Scholar
  • 37 Kushner I, Sehgal A R. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk?.  Arch Intern Med. 2002;  162 867-869
    CrossrefPubMedGoogle Scholar
  • 38 Ridker P M, Buring J E, Cook N R, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.  Circulation. 2003;  107 391-397
    CrossrefPubMedGoogle Scholar
  • 39 Pearson T A, Mensah G A, Alexander R W. et al . Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.  Circulation. 2003;  107 499-511
    CrossrefPubMedGoogle Scholar
  • 40 Bhattacharyya T, Nicholls S J, Topol E J. et al . Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.  JAMA. 2008;  299 1265-1276
    CrossrefPubMedGoogle Scholar
  • 41 Hakonarson H, Thorvaldsson S, Helgadottir A. et al . Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.  JAMA. 2005;  293 2245-2256
    CrossrefPubMedGoogle Scholar
  • 42 Ky B, Burke A, Tsimikas S. et al . The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.  J Am Coll Cardiol. 2008;  51 1653-1662
    CrossrefPubMedGoogle Scholar
  • 43 Levy A P, Levy J E, Kalet-Litman S. et al . Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque.  Arterioscler Thromb Vasc Biol. 2007;  27 134-140
    CrossrefPubMedGoogle Scholar
  • 44 Nicholls S J, Hazen S L. Myeloperoxidase and cardiovascular disease.  Arterioscler Thromb Vasc Biol. 2005;  25 1102-1111
    CrossrefPubMedGoogle Scholar
  • 45 Shishehbor M H, Hazen S L. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome.  Curr Atheroscler Rep. 2004;  6 243-250
    CrossrefPubMedGoogle Scholar
  • 46 Keller T, Zeller T, Peetz D. et al . Sensitive troponin I assay in early diagnosis of acute myocardial infarction.  N Engl J Med. 2009;  361 868-877
    CrossrefPubMedGoogle Scholar
  • 47 Mukherjee D, Topol E J. Pharmacogenomics in cardiovascular diseases.  Curr Probl Cardiol. 2003;  28 317-347
    CrossrefPubMedGoogle Scholar
  • 48 West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.  Lancet. 1996;  348 1339-1342
    CrossrefPubMedGoogle Scholar
  • 49 Downs J R, Clearfield M, Weis S. et al . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA. 1998;  279 1615-1622
    CrossrefPubMedGoogle Scholar
  • 50 Davidson M H, Robinson J G. Safety of aggressive lipid management.  J Am Coll Cardiol. 2007;  49 1753-1762
    CrossrefPubMedGoogle Scholar
  • 51 Jacobson T A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.  Am J Cardiol. 2004;  94 1140-1146
    CrossrefPubMedGoogle Scholar
  • 52 Jacobson T A. Statin safety: lessons from new drug applications for marketed statins.  Am J Cardiol. 2006;  97 44C-51C
    PubMedGoogle Scholar
  • 53 Davidson M H. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.  Expert Opin Drug Saf. 2004;  3 547-557
    CrossrefPubMedGoogle Scholar
  • 54 Kasiske B L, Wanner C, O"Neill W C. An assessment of statin safety by nephrologists.  Am J Cardiol. 2006;  97 82C-85C
    CrossrefPubMedGoogle Scholar
  • 55 McTaggart F, Buckett L, Davidson R. et al . Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.  Am J Cardiol. 2001;  87 28B-32B
    PubMedGoogle Scholar
  • 56 Baigent C, Keech A, Kearney P M. et al . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.  Lancet. 2005;  366 1267-1278
    CrossrefPubMedGoogle Scholar

Dr. med. Felix Post

Universitätsmedizin Mainz
II. Medizinische Klinik für Kardiologie, Angiologie und Intensivmedizin

Langenbeckstraße
55131 Mainz

eMail: post@2-med.klinik.uni-mainz.de

      >